Document is current
Any future updates will be listed below
-
Authors
Motegi, Satoko
Tsuchiya, Atsunori
Iwasawa, Takahiro
Sato, Takeki
Kumagai, Masaru
Natsui, Kazuki
Nojiri, Shunsuke
Ogawa, Masahiro
Takeuchi, Suguru
Sakai, Yosiki
Miyagawa, Shigeru
Sawa, Yoshiki
Terai, Shuji
-
Funding
Funding for this research was provided by:
Lind Pharma, Inc.
- License Information
-
More Information
Article History
Received: 23 August 2021
Accepted: 20 December 2021
First Online: 1 February 2022
Declarations
:
: All animal experiments were conducted in compliance with institutional regulations, and the study protocols were approved by the Institutional Animal Care and Committee of Niigata University.
: N/A.
: Y. Sakai. is the CEO of Lind Pharma, Inc. Y. Sawa and S. Miyagawa are the scientific advisers of Lind Pharma Inc. The ONO-1301 was provided by Lind Pharma Inc.
